The DOI matches its Crossref record; 285 of the 285 references it cites were found in a registry or an index.
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
Open accessAbstract
Abstract: Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients – psychosocial functioning, quality of life, and recovery. These drugs are no longer limited to specific Diagnostic and Statistical Manual of Mental Disorders ( DSM ) categories. Evidence indicates that SGAs show an improved safety and tolerability profile compared with FGAs. The incidence of treatment-emergent extrapyramidal side effects is lower, and there is less impairment of cognitive function and treatment-related negative symptoms. However, treatment with SGAs has been associated with a wide range of untoward effects, among which treatment-emergent weight gain and metabolic abnormalities are of notable concern. The present clinical review aims to summarize the safety and tolerability profile of selected FGAs and SGAs and to link treatment-related adverse effects to the pharmacodynamic profile of each drug. Evidence, predominantly derived from systematic reviews, meta-analyses, and clinical trials of the drugs amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, CPZ, haloperidol, loxapine, and perphenazine, is summarized. In addition, the safety and tolerability profiles of antipsychotics are discussed in the context of the “behavioral toxicity” conceptual framework, which considers the longitudinal course and the clinical and therapeutic consequences of treatment-emergent side effects. In SMI, SGAs with safer metabolic profiles should ideally be prescribed first. However, alongside with safety, efficacy should also be considered on a patient-tailored basis. Keywords: antipsychotics, side effects, tolerability, safety, psychosis, psychiatry
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, preliminary data indicates community exercise can be beneficial and engaging for young people with mental illness, even for those with severe conditions.253,254”
From The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness (2019) · cites this paper as [253]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–285 of 285
Polcwiartek, C., Vang, T., Bruhn, C. H., Hashemi, N., Rosenzweig, M., & Nielsen, J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4411-x · Cited by 37
Mas, S., Gassó, P., Lafuente, A., Bioque, M., Lobo, A., González-Pinto, A. M., Olmeda, M. S., Corripio, I., LLerena, A., Cabrera, B., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.44 · Cited by 36
Self-citationFleischhacker, W. W., Sanchez, R., Johnson, B. R., et al. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283615dba · Cited by 35
Ribe, A. R., Laurberg, T., Laursen, T. M., Charles, M., Vedsted, P., & Vestergaard, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158013 · Cited by 35
Aripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Komossa, K., Rummel‐Kluge, C., Hunger, H., Schwarz, S., El-Sayeh, H. G. G., & Leucht, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub4 · Cited by 35
Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder
Melkersson, K. I., & Hulting, A. L. (2000) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00007539 · Cited by 34
Tsuboi, T., Bies, R. R., Suzuki, T., Mamo, D. C., Pollock, B. G., Graff‐Guerrero, A., Mimura, M., & Uchida, H. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.010 · Cited by 33
Risperidone-induced retrograde ejaculation: case report and review of the literature
Loh, C., Leckband, S. G., Meyer, J. M., et al. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00009 · Cited by 33
Acute and Long-Term Adverse Effects of Antipsychotics
Correll, C. U. (2007) · CNS Spectrums · doi:10.1017/s1092852900015959 · Cited by 33
Self-citationPredictors of the course of tardive dyskinesia in patients receiving neuroleptics
Bergen, J., Kitchin, R., & Berry, G. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90071-7 · Cited by 32
Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence
Gurrera, R. J., Simpson, J., & Tsuang, M. T. (2007) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2006.10.004 · Cited by 32
Roesch-Ely, D., von Einsiedel, R., Kathöfer, S., Schwaninger, M., & Weisbrod, M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1607-a · Cited by 32
Wei, Y. J., Simoni, J. M., Lucas, J. A., & Brandt, N. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw095 · Cited by 32
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654 · Cited by 32
Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research
Fava, G. A., Tossani, E., Bech, P., Berrocal, C., Chouinard, G., Csillag, C., Wittchen, H., & Rief, W. (2014) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1412 · Cited by 31
Zhang, B., Deng, L., Wu, H., Lu, X., Peng, L., Wu, R., Guo, W., Chen, J., Li, L., & Zhao, J. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.06.034 · Cited by 31
Nourian, Z., Mow, T. J., Muftic, D., Burek, S., Pedersen, M. L., Matz, J., & Mulvany, M. J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1064-9 · Cited by 30
Kagal, U. A., Ss, T., Patil, N. M., et al. (2012) · Journal of Pharmacy Practice · doi:10.1177/0897190012442220 · Cited by 30
Rauly‐Lestienne, I., Boutet-Robinet, E. A., Ailhaud, M., Newman‐Tancredi, A., & Cussac, D. (2007) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-007-0182-6 · Cited by 29
Conti, V., Venegoni, M., Cocci, A., Fortino, I., Lora, A., & Barbui, C. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0479-9 · Cited by 29
Ozbilen, M., Adams, C. E., & Marley, J. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803530476 · Cited by 29
Neuroleptic Malignant Syndrome
Selva, A., José, A. S., Jacas, C., et al. (2005) · Van Nostrand's Scientific Encyclopedia · doi:10.1002/0471743984.vse5094 · Cited by 29
Chen, C., Lin, T., Wang, C., & Shuai, H.-A. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02156.x · Cited by 28
A Post Hoc Analysis of Negative Symptoms and Psychosocial Function in Patients With Schizophrenia
Stahl, S. M., MALLA, A. K., Newcomer, J. W., Potkin, S. G., Weiden, P. J., Harvey, P. D., Loebel, A. D., Watsky, E. J., SIU, C. O., & Romano, S. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e69042 · Cited by 28
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia
Tiwari, A. K., Zai, C. C. H., Likhodi, O., Voineskos, A. N., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Remington, G. J., Müller, D., & Kennedy, J. L. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.93 · Cited by 28
Mo, P. K. H., Mak, W. W. S., Chong, E. S. K., Shen, H., & Cheung, R. Y. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107237 · Cited by 27
Increased risk of chronic liver disease in patients with bipolar disorder: A population-based study
Hsu, J., Chien, I., & Lin, C. (2016) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2016.07.006 · Cited by 27
Effect of Risperidone on Prolactinoma Growth in a Psychotic Woman
Pal, J. K., & Sarino, W. A. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200009000-00018 · Cited by 26
Hu, K., Chou, Y., Wen, Y.-H., Hsieh, K., Tsai, J., Yang, P., Yang, Y., & Lin, C. R. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.07.047 · Cited by 26
Shin, J., Choi, N., Lee, J., Seong, J.-M., Park, M.-J., Lee, S. H., & Park, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119931 · Cited by 25
Do Atypical Antipsychotics Really Enhance Smoking Reduction More Than Typical Ones?
Wu, B., Chen, H., & Lee, S.-M. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828b2575 · Cited by 25
Meduri, M., Gregoraci, G., Baglivo, V., Balestrieri, M., Isola, M., & Brambilla, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.033 · Cited by 25
Ronaldson, K. J., Fitzgerald, P. B., & McNeil, J. J. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414566871 · Cited by 25
Risk of breast cancer in risperidone users: A nationwide cohort study
Reutfors, J., Wingård, L., Brandt, L., Wang, Y., Qiu, H., Kieler, H., & Bahmanyar, S. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.10.035 · Cited by 25
Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis
Robles, O., Zabala, A., Bombín, I., Parellada, M., Moreno, D. M., Ruíz-Sancho, A., & Arango, C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp062 · Cited by 24
Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release
Carboni, L., Negri, M., Michielin, F., Bertani, S., Fratte, S. D., Oliosi, B., & Cavanni, P. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000824 · Cited by 24
Mediators of First- Versus Second-generation Antipsychotic-related Mortality in Older Adults
Jackson, J. W., VanderWeele, T. J., Blacker, D., & Schneeweiß, S. (2015) · Epidemiology · doi:10.1097/ede.0000000000000321 · Cited by 23
Vancampfort, D., Stubbs, B., Sienaert, P. A., Wyckaert, S., Hert, M. D., Richards, J. A., Kinyanda, E., & Probst, M. (2016) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2016.1161072 · Cited by 23
Self-citationEffects of antipsychotic drugs on cardiovascular variability in participants with bipolar disorder
Linder, J. R., Sodhi, S. K., Haynes, W. G., & Fiedorowicz, J. G. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2380 · Cited by 22
Achalia, R. M., Chaturvedi, S. K., Desai, G., et al. (2014) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2013.12.010 · Cited by 22
Mortimer, A. M., & Al-Agib, A. O. A. (2007) · International Journal of Social Psychiatry · doi:10.1177/0020764006075000 · Cited by 22
Dietary advice for people with schizophrenia
Pearsall, R., Praveen, K. T., Pelosi, A. J., & Geddes, J. R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009547.pub2 · Cited by 22
Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia
Buoli, M., Kahn, R. S., Serati, M., Altamura, A. C., & Cahn, W. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2542 · Cited by 22
Ono, S., Suzuki, Y., Shindo, M., et al. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01290.x · Cited by 21
Zhai, D., Yan, L., Dong, G., Liu, Y., Wang, X., Zhou, D., Cui, T., Yang, Y., Zhang, W., Zhao, Y. Y., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.10.006 · Cited by 21
Risperidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Hunger, H., Schmidt, F., Schwarz, S., Leucht, S., & Rummel‐Kluge, C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006626 · Cited by 21
Effect of Risperidone on Prolactinoma
Mendhekar, D. N., Jiloha, R. C., & Srivastava, P. K. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-815474 · Cited by 20
Comparative safety of atypical antipsychotics and the risk of pneumonia in the elderly
Mehta, S., Pulungan, Z., Jones, B. T., et al. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3882 · Cited by 20
Pasternak, B., Svanström, H., Ranthe, M. F., Melbye, M., & Hviid, A. P. (2014) · CNS Drugs · doi:10.1007/s40263-014-0176-0 · Cited by 19
Akkaya, C., Büşra, K. A. Y. A., Kotan, Z., Sarandöl, A., Ersoy, C., & Kırlı, S. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091252 · Cited by 19
Babin, S. L., Hood, A. J., Wassef, A. A., Williams, N., Patel, S. S., & Sereno, A. B. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.06.004 · Cited by 19
Bulut, S. D., Bulut, S., Atalan, D. G., Tulacı, R. G., Türker, T., Gürçay, E., & Aydemir, Ç. (2016) · PubMed · Cited by 19
Lee, J., Kim, S., Lee, Y., Kang, H., Kim, S., Bae, K., Kim, J., Shin, I., & Yoon, J. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2489 · Cited by 18
Quetiapine-induced myocarditis presenting as acute STEMI
Wassef, N., Khan, N., & Munir, S. M. (2015) · BMJ Case Reports · doi:10.1136/bcr-2014-207151 · Cited by 18
Gluais, P., Bastide, M., Grandmougin, D., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.06.046 · Cited by 17
DiMascio, A., & Shader, R. I. (1968) · PubMed · Cited by 15
Akathisia and pseudoakathisia: clinical observations and accelerometric recordings.
Rapoport, A., Stein, D., Grinshpoon, A., et al. (1994) · PubMed · Cited by 15
Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report
Ifteni, P. I., Moga, M., Burtea, V., & Correll, C. U. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s70545 · Cited by 15
Self-citationTorstensson, M., Leth-Møller, K., Andersson, C., Torp-Pedersen, C. T., Gislason, G., & Holm, E. (2016) · Age and Ageing · doi:10.1093/ageing/afw209 · Cited by 14
Witkin, J. M., Levant, B., Zapata, A. G., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139212 · Cited by 13
Perroud, N., & Huguelet, P. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.02.010 · Cited by 12
Prevalence and characteristics of patients with pseudoakathisia
Havaki-Kontaxaki, B. J., Kontaxakis, V. P., & Christodoulou, G. N. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00090-0 · Cited by 12
Riedel, M. J., Schmitz, M., østergaard, P. K., Ferrannini, L., Franco, M., Alfano, V., & Vansvik, E. D. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.027 · Cited by 12
The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks
Zdanys, K. F., Carvalho, A. F., Tampi, R. R., et al. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160510121633 · Cited by 12
Self-citationDiMascio, A., Dr, G., & Shader, R. I. (1968) · PubMed · Cited by 10
Nonadherence to Medication Four Years After a First Episode of Psychosis and Associated Risk Factors
Hill, M. B., Crumlish, N., Whitty, P., et al. (2010) · Psychiatric Services · doi:10.1176/appi.ps.61.2.189 · Cited by 10
Wu, B.-J., & Lan, T. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0636-7 · Cited by 9
Altamura, A. C., & Dragogna, F. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413492572 · Cited by 9
Behavioral Toxicity of Psychotropic Drugs
Wittenborn, J. R. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198003000-00008 · Cited by 9
Correli, C. U. (2012) · Schizophrenia Research · doi:10.1016/s0920-9964(12)70211-6 · Cited by 9
[Four years of experience with chlorpromazine in therapy of psychoses].
Delay, J.-C., Deniker, P., & Ropert, R. (1956) · PubMed · Cited by 9
Arcari, G. T., Mendes, A. K., & Sothern, R. B. (2012) · PubMed · Cited by 7
Haloperidol Versus Second-Generation Antipsychotics in the Long-Term Treatment of Schizophrenia
Altamura, A. C., Buoli, M., & Mauri, M. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c989a · Cited by 7
Cariprazine for Schizophrenia and Bipolar Disorder.
Scarff, J. R. (2016) · Europe PMC (PubMed Central) · Cited by 7
(2000) · Time to knit · doi:10.1016/j.ymed.2015.06.007 · Cited by 7
Kluge, M., Schuld, A., Himmerich, H., et al. (2007) · Max Planck Institute for Plasma Physics · Cited by 7
Behavioral toxicity of psychotropic drugs. V. Effects on gross behavior patterns.
DiMascio, A., Shader, R. I., & Gs, H. (1969) · PubMed · Cited by 6
Antipsychotic drugs and risk of venous thromboembolism: nested case-control study
(2011) · BMJ · doi:10.1136/bmj.d112 · Cited by 6
Use of psychotropic drugs during pregnancy and breast‐feeding
Damkier, P., Videbech, P., & Larsen, E. R. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12546 · Cited by 6
Effect of COMT Val108/158Met Genotype on Risk for Polydipsia in Chronic Patients with Schizophrenia
Yamada, K., Shinkai, T., Chen, H., Utsunomiya, K., & Nakamura, J. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8287-9 · Cited by 5
Shiga, T., Yong, S. L., Carino, J. L., et al. (2005) · Anesthesiology · doi:10.1097/00000542-200506000-00016 · Cited by 5
Yang, F., Wang, X., Liu, X., et al. (2011) · Research Online (University of Wollongong) · Cited by 5
Thinking ahead: Executive dysfunction in bipolar disorder
Solé, B., Vieta, E., & Martínez‐Arán, A. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.008 · Cited by 4
Self-citationHsu, W., Esmaily-Fard, A., & Lee, C. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.300 · Cited by 3
Gilmer, T., Henwood, B. F., McGovern, N., Hurst, S., Burgdorf, J. R., & Innes-Gomberg, D. (2017) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-016-0786-6 · Cited by 3
Research works printed but not linked: 1
- [224]De Hert M Vancampfort D Stubbs B Sabbe T Wildiers H Detraux J Antipsychotic treatment, prolactin, and breast tumorigenesis Psychiatr Danub 2016 28 3 243 254 27658833
Cited by
Sorted by citations
OECD (2021) · OECD Health Policy Studies · doi:10.1787/4ed890f6-en · Cited by 407
Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders
Carvalho, A. F., Solmi, M., Sanches, M., Machado, M. O., Stubbs, B., Ajnakina, O., Sherman, C., Sun, Y. R., Liu, C. S., Brunoni, A. R., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0835-5 · Cited by 204
Self-citationVázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
Self-citationSolmi, M., Pigato, G., Kane, J. M., & Correll, C. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s133205 · Cited by 88
Medical Management of Eating Disorders: An Update
Voderholzer, U., Haas, V., Correll, C. U., & Körner, T. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000653 · Cited by 70
Self-citation
Metadata
- Authors
- Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., Correll, C., & Carvalho, A.
- Affiliations
- University of Padua (IT)
- Hospital Clínic de Barcelona (ES)
- Universidad del Desarrollo (CL)
- New York State Psychiatric Institute (US)
- University of Toronto (CA)
- Northwell Health (US)
- ORCID
- Venue
- Therapeutics and Clinical Risk Management
- Publisher
- Informa UK Limited
- Published
- 2017-06
- Volume
- Volume 13
- Pages
- 757-777
- ISSN
- 1176-6336 (ISSN-L)
- 1178-203X
- PMC
- PMC5499790
- OpenAlex
- W2728473268
- Cited by
- 438
- References
- 285
- Citations by year
- 2026: 44 · 2025: 44 · 2024: 48 · 2023: 36 · 2022: 62 · 2021: 55 · 2020: 60 · 2019: 43 · 2018: 39 · 2017: 3
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutics and Clinical Risk Management (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Research Portal (King's College London) (submittedVersion, cc-by-nc)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Funders
- Pfizer
- AstraZeneca
- Sanofi
- Sunovion
- Ministerio de Ciencia e Innovación
- Centro de Investigación Biomédica en Red de Salud Mental
- Servier
- H. Lundbeck A/S
- Comisión Nacional de Investigación Científica y Tecnológica (ACT1414)
- National Institute of Mental Health
- Fondo Nacional de Desarrollo Científico y Tecnológico (ACT1414, 1160736)
- Cilag
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- antipsychotic drugs, typical antipsychotics, atypical antipsychotics, drug safety, tolerability, adverse effects, severe mental illness, extrapyramidal symptoms, weight gain, metabolic abnormalities, negative symptoms, cognitive impairment, chlorpromazine, clozapine, olanzapine, amisulpride, aripiprazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
